Linus Backert

List of Publications by Year in descending order

16 papers	1,399 citations	840776 11 h-index	1125743 13 g-index
17 all docs	17 docs citations	17 times ranked	2329 citing authors

#	Article	IF	Citations
1	HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. , 2021, 9, e002071.		126
2	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Medicine, 2020, 12, 32.	8.2	32
3	A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. , 2019, 7, 307.		39
4	Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. Leukemia and Lymphoma, 2018, 59, 1949-1958.	1.3	4
5	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathologica, 2018, 135, 923-938.	7.7	36
6	HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. OncoImmunology, 2018, 7, e1316438.	4.6	42
7	Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. Cancer Research, 2018, 78, 4627-4641.	0.9	56
8	Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices. Journal of Immunology, 2017, 199, 2639-2651.	0.8	81
9	Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet, The, 2017, 390, 1511-1520.	13.7	350
10	The immunopeptidomic landscape of ovarian carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9942-E9951.	7.1	152
11	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and â€œpan-leukemiaâ€•antigens. Oncotarget, 2017, 8, 43915-43924.	1.8	12
12	Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. PLoS ONE, 2016, 11, e0167017.	2.5	17
13	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cellâ€"based immunotherapy. Blood, 2015, 126, 1203-1213.	1.4	103
14	Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Medicine, 2015, 7, 119.	8.2	178
15	HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E166-75.	7.1	150
16	Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers. Blood, 2015, 126, 1722-1722.	1.4	0